WDC
41
-2
ZTS
47
2
TGNA
53
2
VTR
49
-3
AIG
38
-4
EFX
32
2
MRK
22
3
GRMN
62
-3
DE
46
3
INTU
51
2
RRC
63
3
EIX
77
2
AES
39
-4
SYK
64
-4
AXP
66
2
UHS
54
3
JPM
63
-4
CSX
51
-2
CVS
48
3
BMY
53
-7
WDC
41
-2
ZTS
47
2
TGNA
53
2
VTR
49
-3
AIG
38
-4
EFX
32
2
MRK
22
3
GRMN
62
-3
DE
46
3
INTU
51
2
RRC
63
3
EIX
77
2
AES
39
-4
SYK
64
-4
AXP
66
2
UHS
54
3
JPM
63
-4
CSX
51
-2
CVS
48
3
BMY
53
-7
Financhill
Back

Pliant Therapeutics 10K Form

Sell
39

PLRX
Pliant Therapeutics

Last Price:
12.85
Seasonality Move:
18.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLRX News And Ratings

See the #1 stock for the next 7 days that we like better than PLRX

PLRX Financial Statistics

Sales & Book Value

Annual Sales: $1.58M
Cash Flow: $-33.17M
Price / Cash Flow: 0
Annual Sales: $5.68
Price / Book: 2.17

Profitability

EPS (TTM): -3.34000
Net Income (TTM): $-201.68M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Pliant Therapeutics Earnings Forecast

Key Pliant Therapeutics Financial Ratios

  • The Research & Development expenses have been 8,088.42% of Revenue.
  • The Interest Expense is -0.79% of Operating Income.
  • The Net Earning history of PLRX is -10,211.14% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Pliant Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PLRX
CUSIP: 729139
Website: pliantrx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PLRX Technical Analysis vs Fundamental Analysis

Sell
39
Pliant Therapeutics (PLRX) is a Sell

Is Pliant Therapeutics a Buy or a Sell?